MEDIFAST (MED)
(Delayed Data from NYSE)
$18.30 USD
-0.30 (-1.61%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $18.31 +0.01 (0.05%) 7:22 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.30 USD
-0.30 (-1.61%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $18.31 +0.01 (0.05%) 7:22 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Clorox (CLX) Q3 Earnings Beat & Sales Miss, FY21 View Updated
by Zacks Equity Research
Clorox's (CLX) third-quarter fiscal 2021 earnings beat estimates but declined year over year on lower gross margins and increased advertising investments.
Factors to Watch Ahead of Sysco's (SYY) Q3 Earnings Release
by Zacks Equity Research
Sysco's (SYY) third-quarter fiscal 2021 results are likely to reflect softness in International unit owing to pandemic-led lockdown in various regions. Also, product cost inflation is a concern.
Here's How Medifast (MED) is Placed Ahead of Q1 Earnings
by Zacks Equity Research
Strength in the OPTAVIA lifestyle solution and coaching support system have most likely aided Medifast's (MED) first-quarter 2021 performance.
Altria (MO) Q1 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Altria's (MO) first-quarter performance is hurt by soft cigarette shipment volumes. Nevertheless, higher pricing continue to remain an upside.
What's in Store for The Estee Lauder Companies (EL) Q3 Earnings
by Zacks Equity Research
Strength in the Asia-Pacific region and solid online sales are likely to get reflected in The Estee Lauder Companies' (EL) third-quarter fiscal 2021 performance.
Factors to Watch Ahead of Church & Dwight (CHD) Q1 Earnings
by Zacks Equity Research
Church & Dwight's (CHD) first-quarter 2021 results are likely to reflect gains from the pandemic-led higher at-home consumption, though high marketing costs are likely to be a burden.
Factors to Watch Ahead of Hershey's (HSY) Q1 Earnings Release
by Zacks Equity Research
Hershey's (HSY) first-quarter 2021 results are likely to reflect strength in the North America segment and gains from innovation. However, softness in the International segment is a concern.
Factors to Watch Ahead of Pilgrim's Pride (PPC) Q1 Earnings
by Zacks Equity Research
Pilgrim's Pride's (PPC) first-quarter 2021 results are likely to benefit from a focus on key customers, though softness in the U.S. operations has been a concern.
Factors to Watch Ahead of Kraft Heinz's (KHC) Q1 Earnings
by Zacks Equity Research
Kraft Heinz's (KHC) first-quarter 2021 results are likely to reflect gains from the pandemic-led higher at-home consumption and efficient pricing, though high SG&A costs are concerning.
Helen of Troy (HELE) Queued for Q4 Earnings: Factors to Note
by Zacks Equity Research
Helen of Troy's (HELE) fourth-quarter fiscal 2021 results are likely to reflect gains from Leadership Brands and higher online sales.
Mondelez (MDLZ) Lined Up for Q1 Earnings: Key Things to Note
by Zacks Equity Research
Mondelez's (MDLZ) first-quarter 2021 results are likely to reflect gains from acquisitions and saving efforts amid weakness in some emerging markets and high COVID-19 costs.
Archer Daniels (ADM) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Archer Daniels' (ADM) Q1 revenues are likely to have benefited from momentum in its Nutrition segment, driven by strength in Animal and Human Nutrition businesses.
Philip Morris (PM) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Philip Morris' (PM) first-quarter performance reflects gains from favorable pricing variance as well as growth in heated tobacco shipment volumes.
The Estee Lauder Companies (EL) Looks Radiant: Here's Why
by Zacks Equity Research
The Estee Lauder Companies (EL) Skin Care portfolio is performing well. Also, the company is on track with cost-saving measures.
Factors Likely to Influence Boston Beer's (SAM) Q1 Earnings
by Zacks Equity Research
Boston Beer (SAM) is expected to have benefited from strong depletion and shipment growth as well as innovation in Q1. Also, strength in brands and its cost-saving initiatives bode well.
Kimberly-Clark (KMB) Queued for Q1 Earnings: Factors to Note
by Zacks Equity Research
Kimberly-Clark's (KMB) first-quarter 2021 results are likely to reflect escalated costs and softness in the K-C Professional unit, though the Consumer Tissue segment should offer some respite.
Is Medifast (MED) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Medifast (MED) possesses solid growth attributes, which could help it handily outperform the market.
Medifast (MED) Rallies More Than 25% in 6 Months: Here's Why
by Zacks Equity Research
Medifast (MED) has been benefiting from its OPTAVIA lifestyle solution and coaching support system, which is well placed given consumers' rising inclination toward health and wellness.
Why Is Medifast (MED) Down 11.9% Since Last Earnings Report?
by Zacks Equity Research
Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lamb Weston's (LW) China Investment to Fuel Production Capacity
by Zacks Equity Research
Lamb Weston (LW) unveils plans to build a new french fry processing facility in Ulanqab, Inner Mongolia, China. Additionally, the company declares a quarterly dividend.
Nu Skin (NUS) More Than Doubles in a Year: Innovation a Driver
by Zacks Equity Research
Nu Skin (NUS) is optimistic about momentum in 2021, driven by impressive product pipeline, robust digital efforts along with steady improvement in customers and sales leaders.
The J.M. Smucker's (SJM) Deal With JDE Peet's to Aid Growth
by Zacks Equity Research
The J. M. Smucker (SJM) teams up with JDE Peet's, which is likely to support the former's Away From Home liquid coffee business.
General Mills (GIS) Q3 Earnings Lag Estimates, Sales Grow Y/Y
by Zacks Equity Research
General Mills' (GIS) third-quarter fiscal 2021 results reflect increased at-home demand amid the pandemic. However, high input costs are a concern.
General Mills (GIS) Strikes Deal With Sodiaal to Drive Growth
by Zacks Equity Research
General Mills (GIS) to offload 51% controlling interest in Yoplait S.A.S. to Sodiaal, in exchange of complete ownership of the Canadian Yoplait business.
Medifast (MED) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Medifast (MED) possesses solid growth attributes, which could help it handily outperform the market.